Study on Enasidenib for Treating T-Cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
ClinicalTrials ID:NCT06756308
This clinical trial is exploring whether the drug enasidenib is safe for treating people with a specific type of T-cell lymphoma called angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The study will test enasidenib alone and in combination with another drug, rituximab.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to determine if enasidenib is a safe treatment option for individuals with angioimmunoblastic T-cell lymphoma (AITL) that has a specific genetic change known as an IDH2 mutation. Researchers will evaluate the safety of enasidenib when used by itself or together with the drug rituximab.
Eligibility Criteria
Inclusion Criteria
- Must have a confirmed diagnosis of angioimmunoblastic T-cell lymphoma (AITL) with an IDH2 mutation.
- For patients whose disease has returned or worsened, it must have happened after at least one previous treatment.
- Tumor samples must show at least 5% tumor cells.
- Must be 18 years or older.
- Previous cancer treatments must have been stopped at least two weeks before starting the study treatment.
- If you received localized radiation therapy as your last treatment, you might be able to join the study sooner after discussing with the study doctor.
- Must be able to reduce steroid use to 25 mg/day of prednisone (or equivalent) when starting the study treatment.
- Topical steroids for skin involvement of AITL are allowed.
- Must have a performance status score of 2 or less, meaning you are able to carry out all self-care but unable to carry out any work activities.
- Must meet specific laboratory criteria, which may involve discussions with the study doctor if you need growth factors or blood transfusions to qualify.
Exclusion Criteria
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.